B-vitamin Treatment Modifies the Mortality Risk Associated with Calcium Channel Blockers in Patients with Suspected Stable Angina Pectoris: A Prospective Cohort Study.

ABSTRACT:

Background

Calcium channel blockers (CCBs) are used for the treatment of cardiovascular disease (CVD), including angina pectoris, and hypertension; however, the effect on survival remains uncertain. CCBs impair fibrinolysis and have been linked to elevated plasma homocysteine (Hcy), a CVD risk marker.

Objective

We explored the association between CCB use and mortality in a large prospective cohort of patients with suspected stable angina pectoris (SAP), and potential effect modifications by Hcy-lowering B-vitamin treatment (folic acid, B₁₂, and/or B₆) as 61.8% of the patients participated in a randomized placebo-controlled B-vitamin intervention trial.

Methods

Patient baseline continuous characteristics according to CCB treatment were tested by l

SUBMITTER: Dhar I 

PROVIDER: S-EPMC10375456 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature